Depressive Symptoms and Clinical Status During the Treatment of Adolescent Suicide Attempters (TASA) Study
Drs. Vitiello and Wagner are with the National Institute of Mental Health; Drs. Brent, Bukstein, and Goldstein, and Ms. Zelazny are with the University of Pittsburgh Western Psychiatnc Institute and Clinic; Drs. Greenhill Stanley, Posner, Shen, and Turner, and Ms. Gugga and Ms. Capasso are with the Columbia University-New York State Psychiatric Institute; Drs. Emslie and Kennard, and Ms. Mayes are with the University of Texas Southwestern Medical Center in Dallas; Drs. Wells, Compton, Curry, and March are with the Duke University Medical Center; Dr. Coffey is with the New York University Child Study Center; Drs. Walkup, Cwik, Barnett, and Riddle are with Johns Hopkins University
Accepted 25 June 2009.
Disclosure: Dr. Greenhill was a consultant to Pfizer, served as chairman of DSMB for pediatric ziprasidone triak, and received research grants from the NIMH, Otsuka/Bristol-Myers Squibb, and Johnson & Johnson. Dr. Emslie received research support from Biobehavioral Diagnostics, Forest laboratories, Shire, and Somerset and has been a consultant for Biobehavioral Diagnostics, Eli Lilly, Forest Laboratories, Pfizer, Shire, Validus Pharmaceuticals, and Wyeth Pharmaceuticals. Dr. Bukstein has consulted for Quintiles CME; has served on the speakers' bureau of Quintiles CME; has received research and/or education funding from Shire Pharmaceuticals, Ortho-McNeil Janssen, and Quintiles; and has received book royalties from Routledge. Dr. Walkup receives research support from the NIH, SAMHSA, and the Tourette Syndrome Association. He received free medication and phcebo from Eli Lilly and Pfizer and free medication from Abbott for NIMH-funded clinical tria. He has received honoraria from Eli Lilly in 2006 and from Pfizer in 2003 and 2005 and from the Tourette Syndrome Association in 2007–2008. He also provided consultation to defense council on behalf of GlaxoSmith-Kline (Paxil) in 2007. Dr. Coffey has received research support from the NIMH, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, and Tourette Syndrome Association and has been advisor to Novartis and Jazz Pharmaceuticals. Dr. Posner has received only research support from the following pharmaceutical companies, as part of an effort to help execute the FDA suicidality mandates/requests: Amgen, AstraZeneca Pharmaceuticals, Forest Laboratories, GlaxoSmithKline, i3 Research, Eli Lilly, Johnson & Johnson, H. Lundbeck A/S, Medtronic, Merck & Co., Next Wave Pharmaceuticals, Novo Nordisk A/S, Orexigen Therapeutics, Otsuka Pharmaceuticals, Pfizer, Roche, Sanofi-Aventis, Schering-Plough Corporation, Schwarz Biosciences/UCB, Sepracor, Takeda Pharmaceutical Company, Valeant Pharmaceuticals, Vivus, and Wyeth Research. Dr. March receives research support from the NIMH and NARSAD; is a consultant or scientific advisor to Pfizer, Eli Lilly, Wyeth Pharmaceuticals, GlaxoSmithKline, and MedAvante; receives research support from Pfizer and Eli Lilly; has equity holdings in MedAvante; and receives study drug for NIMH-funded studies from Eli Lilly and Pfizer. Dr. Riddle receives research funding from the NIMH, has served as DSMB member for NLCHD and Johnson & Johnson, and has been a consultant! scientific advisor to Shire and Jazz Pharmaceuticals. Dr. Wagner held stock in Johnson & Johnson in an amount deemed by government-wide regultions not to create a conflict of interest, and has since divested. Drs. Curry and Wells receive speaking fees from the REACH institute. Dr. Turner receives research support from the National Lnstitute of Mental Health. The other authors report no conflicts of interest.
This article was reviewed under and accepted by Ad Hoc Editor Garry Walter, M.D., Ph.D.Funded by the National Institute of Mental Health through cooperative agreement grants MH66750 (PI: K.W., Duke University Medical Center), MH66769 (PI;J. W, Johns Hopkins University), MH66762 (PI: I. G, New York State Psychiatric Institute), MH66775 (PI: D.B., University of Pittsburgh), and MH66778 (PI: G.B., University of Texas Southwestern Medical Center). Data management was funded by an NIMH contract to KAI Research, Rockville, MD.The opinions and assertions contained in this article are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.This article is the subject of an editorial by Dr. Garry Walter in this issue.The authors thank Brian Knizner (project coordinator), Marcie McCullough (data entry), Travis Schermer (interviewer), Angela Aloxe (interviewer), Kim Poling (therapy supervhor, therapist), Nancy Tormey (therapist), Brian McKain (pharma-cotherapht and therapist), Sue Wesner (pharmacotherapht), Allen Chrhman (psychiatrist, pharmacotherapy supervisor), Rameshari Tumuluru (psychiatrist), John Campo (psychiatrist), Joanne Severe (operations), and the NIMH Data and Safety Monitoring Board.Clinical trial registration information–Treatment of Adolescent Suicide Attempters (TASA). URL: http://clinicaltrials.gov. Unique identifier: NCT00080158.
PII: S0890-8567(09)60164-7
doi:10.1097/CHI.0b013e3181b5db66
© 2009 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
